VeriStrat: A prognostic and/or predictive biomarker for advanced lung cancer patients?

Expert Review of Respiratory Medicine

Volumn 8, Issue 1, 2014, Pages 1-4

  Molina Pinelo, Sonia ^a   Pastor, María D ^a   Paz Ares, Luis ^a,b  

^a CSIC   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

advanced NSCLC; EGFR; proteomic signature; serum; tyrosine kinase inhibitors; VeriStrat

Indexed keywords

DOCETAXEL; ERLOTINIB; GEFITINIB; PEMETREXED; PLACEBO;

ADVANCED CANCER; ALGORITHM; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG EFFICACY; EXON; GENE DELETION; HUMAN; LUNG NON SMALL CELL CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PREDICTIVE VALUE; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893076916     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.861744     Document Type: Review

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J. Clin. 63(1), 11-30 (2013).
2. Peters S, Adjei AA, Gridelli C. et al.: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii56-vii64 (2012).
3. Hanna N, Shepherd FA, Fossella FV. et al.: Randomizedphase III trial of pemetrexed versus docetaxel in patients with non-small-celllung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004).
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T. et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
5. Kim ES, Hirsh V, Mok T. et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372(9652), 1809-1818 (2008).
6. Ciuleanu T, Stelmakh L, Cicenas S. et al.: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol. 13(3), 300-308 (2012).
7. Rosell R, Carcereny E, Gervais R. et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFRmutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
8. Shaw AT, Kim DW, Nakagawa K. et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368(25), 2385-2394 (2013).
9. Garassino MC, Martelli O, Broggini M. et al.: Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-Type EGFR tumours (TAILOR): A randomised controlled trial. Lancet Oncol. 14(10), 981-988 (2013).
10. Okano Y, Ando M, Asami K. et al.: Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-Type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J. Clin. Oncol. 31(Suppl.), Abstract 8006 (2013).
11. Taguchi F, Solomon B, Gregorc V. et al.: Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study. J. Natl Cancer Inst. 99(11), 838-846 (2007).
12. Roder J, Roder H, Hunsucker S. et al.: Retrospective Analysis of Study EGF30008 by Mass-Spectrometry Based Serum Assay (VeriStrat-) [Thirty-fourth Annual CTRC-AACR San Antonio Breast Cancer Symposium]. Cancer Research 71, 24 (Suppl. 3), S1-S4 (2011).
13. Milan E, Lazzari C, Anand S. et al.: SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J. Proteomics 76, 91-101 (2012).
14. Hunsucker SH, Grigorieva J, Helfrich BA. et al.: Pre-Treatment sera from NSCLC patients with different outcomes on EGFR-TKI therapy differentially affects sensitivity of lung cancer cell lines to EGFR-TKIs. Cancer Res. 71(8 Suppl.), Abstract LB-306 (2011).
15. Amann JM, Lee JW, Roder H. et al.: Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J. Thorac. Oncol. 5(2), 169-178 (2010).
16. Stinchcombe TE, Roder J, Peterman AH. et al.: A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. J. Thorac. Oncol. 8(4), 443-451 (2013).
17. Carbone DP, Ding K, Roder H. et al.: Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR. 21 trial. J. Thorac. Oncol. 7(11), 1653-1660 (2012).
18. Lazzari C, Novello S, Barni S. et al.: Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE) [2013 ASCO Annual Meeting]. J. Clin. Oncol. 31(Suppl.), Abstract LBA8005 (2013).
19. S. Novello, S. Barni, F. Grossi. et al.: Tissue biomarker analysis in PROSE, a randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (NSCLC). 17th ECCO-38th ESMO -32nd ESTRO European Cancer Congress. Amsterdam, Netherlands, 27 September-1 October (2013).
20. Nelson RE, Stenehjem D, Akerley W. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer doi:10.1016/j. lungcan.2013.08.021 (2013) (Epub ahead of print).